SAJAZIR™ (icatibant) Injection
What is SAJAZIR?
SAJAZIR is an FDA-approved injection indicated for the treatment of acute attacks of hereditary angioedema (HAE) in adults aged 18 years and older.1,2 SAJAZIR comes in the form of a convenient, prefilled injection that you will be trained to self-administer subcutaneously as soon as you notice the signs of an HAE attack coming on.1
At Cycle, we know that supporting people with rare diseases is about more than just the medicine. That’s why we created Cycle Vita™, delivering individualized product support with SAJAZIR to support your experience throughout your journey. With SAJAZIR, HAE control is within easy reach.1
Placeholder Image
*SAJAZIR injection is a prefilled syringe for subcutaneous use.1 Patients should not inject SAJAZIR until they have been trained by their healthcare provider or a Cycle Vita Clinical Education Manager.
SAJAZIR product support available to you
Start your SAJAZIR enrollment here
Download and print the enrollment form, share it with your doctor and discuss why you think SAJAZIR may be suited to your needs.
The first 24hrs
Your Cycle Vita team will quickly get to work with your insurance provider to help you understand your coverage.
If prior authorization is needed, our experienced team will work with your insurer to understand the requirements and provide support to your doctor to ensure documentation and requirements are met.
We will route your SAJAZIR therapy to the appropriate specialty pharmacy and follow-up to ensure swift shipment of your medication.
Additional assistance, when required, throughout your journey
In some cases, an appeal may be needed. Where this is the case, our experienced team will work with your insurer to understand the requirements and provide your doctor with information to help with the appeal.
If you are 18 or older and have commercial insurance, you may be eligible for the Cycle Vita Co-Pay Assistance Program. This program will help cover the cost of insurance co-pays for SAJAZIR at 100%, up to the program maximum, for those who are eligible. Please contact our team to find out more about this and other programs that may be available to you (such as Bridge Program, etc.).
A free supply of SAJAZIR while we help secure appropriate Benefit Verification and assist with Prior Authorization activities, as necessary. It may also be requested if you experience a temporary disruption in therapy due to insurance coverage.
Our proactive team will remind your doctor when your SAJAZIR prescription needs to be renewed, in a timely manner, to ensure an uninterrupted supply of your therapy.
We provide product support to help you manage every aspect of your SAJAZIR therapeutic routine, such as clinical education and 1-to-1 injection training either at home or in-clinic.
Translation services are available on request.
What is HAE?
HAE is a rare and life-long, genetic condition that affects somewhere between 1 in 10,000-50,000 people. HAE is usually caused by a shortage or malfunctioning of a protein called C1 esterase inhibitor (C1-INH), known as Type I and Type II. A third group, HAE with Normal C1-Inhibitor (HAE-nl-C1INH, formerly known as Type III), is characterized by patients having functional C1-INH.
HAE Type I, Type II and HAE-nl-C1INH share similar symptoms of unpredictable and recurring swelling that are linked to the overproduction of another protein called bradykinin.3–8
During an HAE attack, fluid in the blood vessels leaks out into the surrounding area, causing painful and sometimes disfiguring swelling.3,4,7 It most commonly affects the face, feet, hands, stomach, genitals and sometimes the throat.1,3–7 Attacks on the throat happen less often but they can be life-threatening, as swelling here can interfere with your breathing.4–6 If you experience an HAE attack affecting your airways, inject SAJAZIR and then go to the nearest hospital emergency room right away.1
Exactly where in the body, how often and how severe is different for everyone and can change over time.3 Because HAE is so rare, it can be difficult to diagnose in the beginning and symptoms are often confused with other conditions, such as allergies.7 Living with HAE is a journey, but with Cycle Vita, you are never alone. The team is here to support you for life.
Resources
Footnote
*Some areas of support may not be accessible to all patients. Eligibility criteria may apply to ensure compliance with all applicable federal and state requirements, and benefits may be limited to commercially insured patients only. For more detailed information about eligibility, terms and conditions, please contact the Cycle Vita team at 888-360-8482.
SAJAZIR™ is a trademark of Cycle Pharmaceuticals Limited in the United States.
References
- SAJAZIR™ (icatibant) Injection. Prescribing Information. Cycle Pharmaceuticals Limited.
- FDA. FDA-approved Drugs. Available at: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022150 [Accessed: September 20 2024].
- Maurer M, et al. Allergy. 2018;73(8):1575–1596.
- Zuraw BL, et al. J Allergy Clin Immunol Pract. 2013;1(5):458–467.
- El-Shanawany T. Hereditary Angioedema. British Society for Immunology. Available at: https://www.immunology.org/public-information/bitesized-immunology/immune-dysfunction/hereditary-angioedema [Accessed: September 20 2024].
- Ghazi A, Grant JA. Biologics. 2013;7:103–113.
- Lumry W, et al. Journal of Infusion Nursing. 2020;43(3):134–145.
- Anderson, J., Soteres, D., Mellor, J., Connolly, H., Kieran Wynne-Cattanach, Earl, L., Schultz, B.G. and Juethner, S. (2024). Physician- and patient-reported outcomes by hereditary angioedema type: Data from a real-world study. Allergy and Asthma Proceedings, [online] 45(4), pp.247–254. Available at: https://doi.org/10.2500/aap.2024.45.240021 [Accessed: October 22 2024].